New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

ISENTRESS® (raltegravir) Film-Coated Tablets, for oral use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

ISENTRESS is a prescription medicine. ISENTRESS is used for HIV infection Treatment.
INDICATIONS AND USAGE
ISENTRESS is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated:
• In combination with other antiretroviral agents for the treatment of HIV-1 infection.
The safety and efficacy of ISENTRESS have not been established in children less than 2 years of age.
DOSAGE FORMS & STRENGTHS
• Film-Coated Tablets: 400 mg (3).
• Chewable Tablets: 100 mg scored and 25 mg.
Manufactured By: Merck
Sharp & Dohme Corp.
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “ISENTRESS® (raltegravir) Film-Coated Tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Raltegravir (RAL), sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure.

Raltegravir was approved for medical use in the United States in 2007. It is on the World Health Organization’s List of Essential Medicines. Lamivudine/raltegravir, a combination with lamivudine, is also available.

Related Products